Pioglitazone leads to lower Dementia risk
17 Feb 2023 • According to current research, elderly people with newly diagnosed type 2 diabetes mellitus (T2DM) with a history of ischemic heart disease or stroke benefit most from treatment with pioglitazone against dementia. Patients who took pioglitazone had a 16% lower overall risk of developing dementia over an average of 10 years compared to peers who did not take the drug, according to a large cohort research from Korea. Nevertheless, the reduction in dementia risk was 54% in people with ischemic heart disease and 43% in people who had previously experienced a stroke. It is speculated that pioglitazone's ability to prevent dementia may be linked to a improving blood vessel's health. Risk for dementia is doubled in adults with T2DM. This prompted Kim and colleagues to research pioglitazone's impact on dementia risk overall, as well as in relation to stroke and ischemic heart disease. Users of pioglitazone had a statistically significant 16% decreased risk of having dementia from all causes than nonusers. There was evidence of a dose-response connection; dementia risk was lower in pioglitazone users who got the greatest cumulative daily dose. The researchers remark that this data suggests the possibility of using pioglitazone as a tailored therapeutic strategy for the prevention of dementia in this subgroup of diabetic individuals.
Source: Medscape | Read full story